QRK207 will be the first trial to use a potential neuroprotective therapy delivered early to reduce the permanent injury and lessen the vision loss from acute NAION. We do not know if the 14-day window for enrollment will be too long to see an effect, but the length of time NAION-associated optic disc swelling typically lasts, as well as the need to recruit sufficient number of subjects for the study, justify this time window, particularly given the low frequency of NAION and the common several-day delay in seeking medical attention by patients who experience the disorder. Except for thrombolysis in ischemic stroke studies, previous treatment of ischemic injury of the central nervous system including neuroprotective agents, has not been effective. None of these failed treatments worked through mechanisms that decreased apoptosis. Furthermore, oral administration of an agent intended to reduce excitatory neurotoxins hypothesized to worsen neuronal injury in glaucoma has also failed. Thus, this treatment trial, which assesses the efficacy and safety of IVT administration of QPI-1007 to avoid the potential complications of systemically administered therapy, could be the first to show optic nerve protection in patients with NAION. Finally, this study is the first clinical trial that effectively partners the NORDIC with industry. We are truly excited to be a part of this clinical trial.
ASJC Scopus subject areas
- Clinical Neurology